Genotype distribution of VDR Gene Bsm-I polymorphisms in different inheritance models in the MS patients and control group
| a) Bsm-I Recessive Model | ||||
|---|---|---|---|---|
| G/G or G/A | A/A | Total | p | |
| MS-Control | ||||
| Control | 83.3% (n=169) | 16.7% (n=34) | 100% (n=203) | |
| MS | 80.1% (n=217) | 19.9% (n=54) | 100% (n=271) | 0.379 |
| Total | 81.4%(n=386) | 18.6% (n=88) | 100% (n=474) | |
| b) Bsm-I Dominant Model | ||||
| G/G | G/A or A/A | Total | p | |
| MS-Control | ||||
| Control | 36.9% (n=75) | 63.1% (n=128) | 100% (n=203) | |
| MS | 35.8% (n=97) | 64.2% (n=174) | 100% (n=271) | 0.796 |
| Total | 36.3%(n=172) | 63.7% (n=302) | 100% (n=474) | |
| c) | Bsm-I Homozygote Model | |||
| G/G | A/A | Total | p | |
| MS-Control | ||||
| Control | 68.8% (n=75) | 31.2% (n=34) | 100% (n=88) | |
| MS | 64.2% (n=97) | 35.8% (n=54) | 100% (n=172) | 0.442 |
| Total | 33.8%(n=88) | 66.2% (n=172) | 100% (n=260) | |
| d) | Bsm-I Heterozygote Model | |||
| G/G | G/A | Total | p | |
| MS-Control | ||||
| Control | 44.4% (n=75) | 55.6% (n=94) | 100% (n=169) | |
| MS | 44.7% (n=97) | 55.3% (n=120) | 100% (n=217) | 0.950 |
| Total | 55.4%(n=214) | 44.6% (n=172) | 100% (n=386) | |
Primers used for amplification of polymorphism sites on the VDR gene_
| Polymorphism | Forward Primer | Reverse Primer |
|---|---|---|
| Fok-I (rs2228570) | AGGATGCCAGCTGGCCCTGGCAC | TGGCTGTGAGCGCCGCATGTTCCATG |
| Bsm-I (rs1544410) | TCCTTGAGCCTCCAGTCCAGG | GCAACCTGAAGGGAGACGTAGC |
| Taq-I (rs731236) | AGAGCATGGACAGGGAGCAAGGC | TAGCTTCATGCTGCACTCAGGCTGG |
Genotype distribution of VDR Gene Fok-I polymorphisms in different inheritance models in the MS patients and control group
| a) | Fok-I Recessive Model | |||
|---|---|---|---|---|
| T/C or TT | C/C | Total | p | |
| MS-Control | ||||
| Control | 52.2% (n=106) | 47.8% (n=97) | 100% (n=203) | |
| MS | 58.3% (n=158) | 41.7% (n=113) | 100% (n=271) | 0.187 |
| Total | 55.7%(n=264) | 44.3% (n=210) | 100% (n=474) | |
| b) | Fok-I Dominant Model | |||
| T/T | T/C or C/C | Total | p | |
| MS-Control | ||||
| Control | 13.3% (n=27) | 86.7% (n=176) | 100% (n=203) | |
| MS | 22.5% (n=61) | 77.5% (n=210) | 100% (n=271) | 0.011 |
| Total | 18.6%(n=88) | 81.4% (n=386) | 100% (n=474) | |
| c) | Fok-I Homozygote Model | |||
| T/T | C/C | Total | p | |
| MS-Control | ||||
| Control | 21.8% (n=27) | 78.2% (n=97) | 100% (n=124) | |
| MS | 35.1% (n=61) | 64.9% (n=113) | 100% (n=174) | 0.013 |
| Total | 29.5%(n=88) | 70.5% (n=210) | 100% (n=298) | |
| d) | Fok-I Heterozygote Model | |||
| T/T | T/C | Total | p | |
| MS-Control | ||||
| Control | 25.5% (n=27) | 74.5% (n=79) | 100% (n=106) | |
| MS | 38.6% (n=61) | 61.4% (n=97) | 100% (n=158) | 0.026 |
| Total | 33.8%(n=88) | 66.7% (n=176) | 100% (n=264) | |
Distribution of VDR gene Polymorphisms within gender in MS patients
| a) | Bsm-I Genotype | ||||
|---|---|---|---|---|---|
| G/G | G/A | A/A | Total | p | |
| Gender | |||||
| Female | 37.2% (n=70) | 43.6% (n=82) | 19.1% (n=36) | 100% (n=188) | |
| Male | 32.5% (n=27) | 45.8% (n=38) | 21.7% (n=18) | 100% (n=83) | 0.740 |
| Total | 35.8% (n=97) | 44.3% (n=120) | 19.9% (n=54) | 100% (n=271) | |
| b) | Fok-I Genotype | ||||
| T/T | T/C | C/C | Total | p | |
| Gender | |||||
| Female | 22.3% (n=42) | 33.0% (n=62) | 44.7% (n=84) | 100% (n=188) | |
| Male | 22.9% (n=19) | 42.2% (n=35) | 34.9% (n=29) | 100% (n=83) | 0.262 |
| Total | 22.5% (n=61) | 35.8% (n=97) | 41.7% (n=113) | 100% (n=271) | |
| c) | Taq-I Genotype | ||||
| C/C | C/T | T/T | Total | p | |
| Gender | |||||
| Female | 34.6% (n=65) | 41.0% (n=77) | 24.5% (n=46) | 100% (n=188) | |
| Male | 28.9% (n=24) | 39.8% (n=33) | 31.3% (n=26) | 100% (n=83) | 0.449 |
| Total | 32.8% (n=89) | 40.6% (n=110) | 26.6% (n=72) | 100% (n=271) | |
Genotype distribution and allele frequency of VDR Fok-I polymorphism in MS patients and healthy controls_
| a) | Fok-I Genotype | |||||
|---|---|---|---|---|---|---|
| T/T | T/C | C/C | Total | p | Power (%) | |
| MS-Control | ||||||
| Control | 13.3% (n=27) | 38.9% (n=79) | 47.8% (n=97) | 100%(n=203) | 0.037 | |
| MS | 22.5% (n=61) | 35.8% (n=97) | 41.7% (n=113) | 100%(n=271) | 100 | |
| Total | 18.6% (n=88) | 37.1% (n=176) | 44.3% (n=210) | 100%(n=474) | ||
| MS subtypes | ||||||
| Control | 13.3% (n=27) | 38.9% (n=79) | 47.8% (n=97) | 100%(n=203) | ||
| RRMS SPMS | 23.3% (n=43) 21.1% (n=18) | 33.2% (n=61) 42.4% (n=36) | 43.5% (n=80) 36.5% (n=31) | 100%(n=184) 100%(n=85) | 0.074 | 100 |
| PPMS | 0.0% (n=0) | 0.0% (n=0) | 100%.0 (n=2) | 100%(n=2) | ||
| Total | 18.6% (n=88) | 37.1% (n=176) | 44.3% (n=210) | 100%(n=474) | ||
| b) | Fok-I Allele | |||||
| T | C | Total | p | Power (%) | ||
| MS-Control | ||||||
| Control | 32.8% (n=133) | 67.2% (n=273) | 100% (n=406) | |||
| MS | 40.4% (n=219) | 59.6% (n=323) | 100% (n=542) | 0.016 | 100 | |
| Total | 37.1% (n=352) | 62.9% (n=596) | 100% (n=948) | |||
| MS subtypes | ||||||
| Control | 32.8% (n=133) | 67.2% (n=273) | 100% (n=406) | |||
| RRMS | 39.9% (n=147) | 60.1% (n=221) | 100% (n=368) | |||
| SPMS | 42.4% (n=72) | 57.6% (n=98) | 100% (n=170) | 0.030 | 100 | |
| PPMS | 0.0% (n=0) | 100.0% (n=4) | 100% (n=4) | |||
| Total | 37.1% (n=352) | 62.9% (n=596) | 100% (n=948) | |||
Genotype distribution of VDR Gene Taq-I polymorphisms in different inheritance models in the MS patients and control group
| a) | Taq-I Recessive Model | |||
|---|---|---|---|---|
| T/C or T/T | C/C | Total | p | |
| MS-Control | ||||
| Control | 62.6% (n=127) | 37.4% (n=76) | 100% (n=203) | |
| MS | 67.2% (n=182) | 32.8% (n=89) | 100% (n=271) | 0.299 |
| Total | 65.2%(n=309) | 34.8% (n=165) | 100% (n=474) | |
| b) | Taq-I Dominant Model | |||
| T/T | T/C or C/C | Total | p | |
| MS-Control | ||||
| Control | 16.7% (n=34) | 83.3% (n=169) | 100% (n=203) | |
| MS | 26.6% (n=72) | 73.4% (n=199) | 100% (n=271) | 0.011 |
| Total | 22.4%(n=106) | 77.6% (n=368) | 100% (n=474) | |
| c) | Taq-I Homozygote Model | |||
| T/T | C/C | Total | p | |
| MS-Control | ||||
| Control | 30.9% (n=34) | 69.1% (n=76) | 100% (n=110) | |
| MS | 44.7% (n=72) | 55.3% (n=89) | 100% (n=161) | 0.022 |
| Total | 39.1%(n=106) | 60.9% (n=165) | 100% (n=271) | |
| d) | Taq-I Heterozygote Model | |||
| T/T | T/C | Total | p | |
| MS-Control | ||||
| Control | 26.8% (n=34) | 73.2% (n=93) | 100% (n=127) | |
| MS | 39.6% (n=72) | 60.4% (n=110) | 100% (n=182) | 0.020 |
| Total | 34.3%(n=106) | 65.7% (n=203) | 100% (n=309) | |
Genotype distribution and allele frequency of VDR Taq-I polymorphism in MS patients and healthy controls_
| a) | Taq-I Genotype | |||||
|---|---|---|---|---|---|---|
| C/C | C/T | T/T | Total | p | Power (%) | |
| MS-Control | ||||||
| Control | 16.7% (n=34) | 45.8% (n=93) | 37.5% (n=76) | 100%(n=203) | 0.040 | |
| MS | 26.6% (n=72) | 40.6% (n=110) | 32.8% (n=89) | 100%(n=271) | 99 | |
| Total | 22.4% (n=106) | 42.8% (n=203) | 34.8% (n=165) | 100%(n=474) | ||
| MS subtypes | ||||||
| Control | 16.7% (n=34) | 45.8% (n=93) | 37.5% (n=76) | 100%(n=203) | ||
| RRMS | 23.9% (n=44) | 43.5% (n=80) | 32.6% (n=60) | 100%(n=184) | ||
| SPMS | 32.9% (n=28) | 34.2% (n=29) | 32.9% (n=28) | 100%(n=85) | 0.101 | 100 |
| PPMS | 0.0% (n=0) | 50.0% (n=1) | 50.0% (n=1) | 100%(n=2) | ||
| Total | 22.4% (n=106) | 42.8% (n=203) | 34.8% (n=165) | 100%(n=474) | ||
| b) | Taq-I Allele | |||||
| T | C | Total | p | Power (%) | ||
| MS-Control | ||||||
| Control | 60.3% (n=245) | 39.7% (n=161) | 100% (n=406) | 0.027 | ||
| MS | 53.1% (n=288) | 46.9% (n=254) | 100% (n=542) | 99 | ||
| Total | 56.2% (n=533) | 43.8% (n=415) | 100% (n=948) | |||
| MS subtypes | ||||||
| Control | 60.3% (n=245) | 39.7% (n=161) | 100% (n=406) | |||
| RRMS | 54.3% (n=200) | 45.7% (n=168) | 100% (n=368) | |||
| SPMS | 50.0% (n=85) | 50.0% (n=85) | 100% (n=170) | 0.087 | 100 | |
| PPMS | 75.0% (n=3) | 25.0% (n=1) | 100% (n=4) | |||
| Total | 56.2% (n=533) | 43.8% (n=415) | 100% (n=948) | |||
Distribution of VDR gene allele within gender in MS patients
| a) | Bsm-I Allele | |||
|---|---|---|---|---|
| G | A | Total | p | |
| Gender | ||||
| Female | 61.7% (n=153) | 38.3% (n=95) | 100% (n=248) | |
| Male | 48.0% (n=49) | 52.0% (n=53) | 100% (n=102) | 0.019 |
| Total | 57.7%(n=202) | 42.3% (n=148) | 100% (n=350) | |
| b) | Fok-I Allele | |||
| T | C | Total | p | |
| Gender | ||||
| Female | 29.0% (n=72) | 71.0% (n=176) | 100% (n=248) | 0.800 |
| Male | 30.4% (n=31) | 71.0% (n=69.6) | 100% (n=102) | |
| Total | 55.7%(n=264) | 70.6% (n=247) | 100% (n=350) | |
| c) | Taq-I Allele | |||
| T | C | Total | p | |
| Gender | ||||
| Female | 37.5% (n=93) | 37.4% (n=76) | 100% (n=248) | 0.137 |
| Male | 46.1% (n=47) | 53.9% (n=55) | 100% (n=102) | |
| Total | 40.0%(n=140) | 60.0% (n=210) | 100% (n=350) |
Genotype distribution and allele frequency of VDR Bsm-I polymorphism in MS patients and healthy controls_
| a) | Bsm-I Genotype | |||||
|---|---|---|---|---|---|---|
| G/G | G/A | A/A | Total | p | Power (%) | |
| MS-Control | ||||||
| Control | 37.0% (n=75) | 46.3% (n=94) | 16.7% (n=34) | 100% (n=203) | 0.677 | |
| MS | 35.8% (n=97) | 44.3% (n=120) | 19.9% (n=54) | 100% (n=271) | 100 | |
| Total | 36.3% (n=172) | 45.1% (n=214) | 18.6% (n=88) | 100% (n=474) | ||
| MS subtypes | ||||||
| Control | 37.0% (n=75) | 46.3% (n=94) | 16.7% (n=34) | 100% (n=203) | ||
| RRMS | 35.9% (n=66) | 46.7% (n=86) | 17.4% (n=32) | 100% (n=184) | ||
| SPMS | 35.3% (n=30) | 38.8% (n=33) | 25.9% (n=22) | 100% (n=85) | 0.622 | 100 |
| PPMS | 50.0% (n=1) | 50.0% (n=1) | 0.0% (n=0) | 100% (n=2) | ||
| Total | 36.3% (n=172) | 45.1% (n=214) | 18.6% (n=88) | 100% (474) | ||
| b) | Bsm-I Allele | |||||
| G | A | Total | p | Power (%) | ||
| MS-Control | ||||||
| Control | 60.1% (n=244) | 39.9% (n=162) | 100% (n=406) | |||
| MS | 57.9% (n=314) | 42.1% (n=228) | 100% (n=542) | 0.503 | 100 | |
| Total | 58.9%(n=558) | 41.1% (n=390) | 100% (n=948) | |||
| MS subtypes | ||||||
| Control | 60.1% (n=244) | 39.9% (n=162) | 100% (n=406) | |||
| RRMS | 59.2% (n=218) | 40.8% (n=150) | 100% (n=368) | 0.589 | ||
| SPMS | 54.7% (n=93) | 45.3% (n=77) | 100% (n=170) | 100 | ||
| PPMS | 75.0% (n=3) | 25.0% (n=1) | 100% (n=4) | |||
| Total | 58.8% (n=558) | 41.2% (n=390) | 100% (n=948) | |||